Know Cancer

forgot password

The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression

20 Years
80 Years
Not Enrolling
Gastric Cancer

Thank you

Trial Information

The Role of Endogenous Antiangiogenic Factors in Gastric Cancer Progression

Gastric cancers have been known to secrete the proangiogenic cytokine VEGF in vitro and in
vivo. Tumor VEGF expression is correlated with the severity of disease in patients with
gastric cancer and some authors have suggested using circulating VEGF as a prognostic factor
or tumor marker.In addition to producing proangiogenic cytokines, recent data demonstrate
that tumors can produce antiangiogenic cytokine as well. It has been suggested that, in
humans, the generation of antiangiogenic compounds in the presence of a primary tumor
suppresses the growth of distant metastases. This phenomenon has been demonstrated in mice
and in patients with clear cell renal cancer, breast cancer, and colorectal cancer. However,
the presence of endogenous antiangiogenic cytokines in patients with gastric cancer has not
been reported.

Inclusion Criteria:

- Histologic diagnosis of gastric adenocarcinoma

- No other forms of cancer therapy, such as chemotherapy or radiotherapy for at least 3
weeks before the enrollment in study

- Performance status of 0, 1, 2 on the ECOG criteria

- ASA class I, II

- Patient compliance that allow adequate follow up

- Informed consent from patient or patient's relative.

Exclusion Criteria:

- Second primary malignancy

- EMR (Endoscopic mucosal resection) indication

- Laparoscopic gastrectomy

- Radiologic or clinical evidence of metastasis

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Relationship between antiangiogenic factor and tumor, node, metastasis

Outcome Time Frame:

One year

Safety Issue:


Principal Investigator

Jun Ho Lee, M.D., Ph.D

Investigator Role:

Principal Investigator

Investigator Affiliation:

Gastric Cancer Branch, National Cancer Center


South Korea: Korea Food and Drug Administration (KFDA)

Study ID:

NCCCTS 04-105



Start Date:

April 2006

Completion Date:

January 2012

Related Keywords:

  • Gastric Cancer
  • gastric cancer
  • antiangiogenic factors
  • TNM stage
  • Stomach Neoplasms